SGLT2 Inhibitors vs DPP-4 Inhibitors on Major Liver Outcomes in Metabolic Dysfunction–Associated Steatotic Liver Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease
Diabetes Obes Metab 2024 Aug 12;[EPub Ahead of Print], TH Shen, ES Aby, D Vock, JF FarleyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.